Business
Genentech to Present New Data Advancing Its Obesity Portfolio at the American Diabetes Association’s 2026 Scientific Sessions
SOUTH SAN FRANCISCO, Calif., June 01, 2026--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that new data from its obesity portfolio will be presented at the 2026 Scientific Sessions of the American Diabetes Association® (ADA). The insights demonstrate significant progress in addressing a range of unmet needs for people living with obesity or overweight such as long-term treatment adherence, which could be supported by a favorable safety and tolerability prof
About this update from Roche Holding Ltd
SOUTH SAN FRANCISCO, Calif., June 01, 2026 --( BUSINESS WIRE )--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that new data from its obesity portfolio will be presented at the 2026 Scientific Sessions of the American Diabetes Association ® (ADA). The insights demonstrate significant progress in addressing a range of unmet needs for people living with obesity or overweight such as long-term treatment adherence, which could be supported by a favorable safety and tolerability profile. "The data we will present at ADA highlight the growing strength of our obesity portfolio, exemplified by the robust efficacy and distinct tolerability profiles of enicepatide and petrelintide," said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. "The clinical insights from these studies demonstrate how our portfolio may offer more tailored, individualized treatment options for people living with obesity." The data presented on Genentech’s obesity assets include: Genentech continues to advance its weight management pipeline rapidly, moving both enicepatide and petrelintide into Phase III development while initiating a Phase II multi-arm combination trial in mid-2026. Genentech is pleased to invite investors and analysts to participate in a virtual event on Monday, June 8, 2026, that will highlight the new data from the Phase II CT388-103 study of enicepatide, as well as from the Phase II ZUPREME-1 study of petrelintide. Additional details on presentations at the ADA’s Scientific Sessions are included below and the full abstracts will be available in Diabetes . About Enicepatide (CT-388) Enicepatide is an investigational once-weekly subcutaneous injectable, dual GLP-1/GIP receptor agonist being developed for the treatment of people living with obesity and associated comorbidities including type 2 diabetes (T2D). Enicepatide was designed to have potent activity on both the GLP-1 and GIP receptors but with minimal to no beta-arrestin recruitment on either receptor. This biased signalling significantly minimizes receptor internalization and consequent desensitization, which is expected to lead to prolonged pharmacological activity. About Petrelintide Petrelintide is an investigational long-acting amylin analog suitable for once-weekly subcutaneous administration that has been designed with chemical and physical stability with no fibrillation around neutral pH, allowing for co-formulation and co-administration with other peptides. 1 Amylin is produced in the pancreatic beta cells and co-secreted with insulin in response to ingested nutrients. Amylin receptor activation has been shown to reduce body weight by restoring sensitivity to the satiety hormone leptin 2,3 inducing a sense of feeling full faster. About Obesity Obesity is recognized as the greatest single risk factor for chronic disease globally. The condition is associated with many health challenges and more than 200 comorbidities, including type 2 diabetes, cardiovascular diseases, fatty liver, and chronic kidney disease. By 2035, over four billion people (more than half of the global population) are projected to be living with excess weight or obesity, a trend affecting nearly every country. This rise is driven by a complex mix of genetics and biology as well as behavioral, environmental and socioeconomic factors, placing an increased strain on healthcare systems due to the associated burden of comorbidities and reduced quality of life. About Genentech Founded 50 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit http://www.gene.com . References 1 Eriksson et al. Presentation at ObesityWeek, November 1–4, 2022, San Diego, CA. Link: https://www.zealandpharma.com/media/0gnfxg4b/zp8396-sema-coformulation-obesityweek-2022.pdf . 2 Mathiesen et al. Eur J Endocrinol 2022;186(6):R93–R111 3 Roth et al. Proc Natl Acad Sci U S A 2008;105(20):7257–7262 View source version on businesswire.com: https://www.businesswire.com/news/home/20260531568623/en/ Contacts Media Contact: Meghan Hindman (650) 467-6800 Advocacy Contact: Danielle Haney (240) 805-4810 Investor Contacts: Loren Kalm (650) 225-3217 Bruno Eschli +41 61 687 5284